Sallmann S, Fiebig B, Hedrich C M, Heubner G, Gahr M
Klinik und Poliklinik für Kinderheilkunde und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden.
Z Rheumatol. 2006 Nov;65(7):576-8, 580-2, 584-5. doi: 10.1007/s00393-006-0115-7.
Children and adolescents represent 15-20% of all systemic lupus erythematosus (SLE) patients. Although the clinical presentation and immunological findings are similar to those of adult SLE, children usually have a more severe disease at onset with higher rates of organ involvement. Rapid diagnosis and subsequent therapy are necessary to prevent major organ damage. The survival of children with SLE has improved dramatically over the past decades due to the introduction of steroids and immunosuppressive drugs. New strategies to improve the long-term course of the disease and to reduce potential drug toxicities are necessary. A common concept does not exist. There are some promising new drugs. This review article summarizes the epidemiology, pathogenesis, clinical manifestations and therapy of childhood and adolescent-onset SLE.
儿童和青少年占所有系统性红斑狼疮（SLE）患者的15%-20%。尽管临床表现和免疫检查结果与成人SLE相似，但儿童通常起病时病情更严重，器官受累率更高。快速诊断及后续治疗对于预防主要器官损害很有必要。由于类固醇和免疫抑制药物的应用，过去几十年来SLE患儿的生存率有了显著提高。有必要采取新策略来改善疾病的长期病程并降低潜在的药物毒性。目前尚无通用的理念。有一些有前景的新药。这篇综述文章总结了儿童及青少年期起病的SLE的流行病学、发病机制、临床表现及治疗。
